Compare DexCom, Inc. (DXCM) vs ThredUp Inc (TDUP) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

ThredUp (TDUP) trades at $6.75, up 6.47% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 revenue growth of 15% year-over-year to $81.7M and a strong gross margin of 79.4%. Recent developments include the launch of a peer-to-peer marketplace and AI-powered shopping tools. Analyst sentiment remains positive with 57% buy ratings and a $6.90 consensus price target, though the company continues to report net losses.

TDUP presents a turnaround story with improving revenue trends and cost management, but profitability remains elusive. The stock offers potential upside to analyst targets if execution continues, though risks include persistent losses, competitive pressures, and the need to achieve sustainable positive EBITDA. Current valuation at 2.58x sales appears reasonable for the growth trajectory.